FDA’s Peter Marks talks reimbursement of gene therapies that win accelerated approval

LOS ANGELES — “Everyone who thinks that the drug should be approved, raise your right hand, and everyone who thinks the drug should not be approved, raise your left hand.” Keith Wonnacott, Lexeo Therapeutics’ VP of regulatory affairs, queried a full audience about whether it thought Sarepta’s gene therapy for…

Click to view original post